Collectively, these studies, along with our recent report on NKTT320 mAb [28], warrant further development of anti-iTCR mAbs that can be used alone or in conjunction with cytokines (such as IL-12 and/or IL-18) or chemotherapeutic agents to reduce the toxicity associated with these agents while enhancing iNKT cell anti-tumor immunity against various cancers. The gene discussed is IL18; the disease is neoplasm.